Danielle A Scott1, Rita Casadonte2, Barbara Cardinali3, Laura Spruill4, Anand S Mehta1, Franca Carli5, Nicole Simone6, Mark Kriegsmann7, Lucia Del Mastro8, Joerg Kriegsmann2, Richard R Drake1. 1. Department of Cell and Molecular Pharmacology and Experimental Therapeutics and MUSC Proteomics Center, Medical University of South Carolina, Charleston, 29425, SC, USA. 2. Proteopath GmbH, Trier, 54296, Germany. 3. Department of Medical Oncology, Ospedale Policlinico San Martino, Genova, 16132, GE, Italy. 4. Department of Pathology and Laboratory Medicine, Medical University of South Carolina, Charleston, 29425, SC, USA. 5. Department of Surgical Pathology, Ospedale Policlinico San Martino, Genova, 16132, GE, Italy. 6. Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, 19107, PA, USA. 7. Institute of Pathology, University of Heidelberg, Heidelberg, 69117, Germany. 8. Department of Internal Medicine, University of Genova, Genova, 16132, GE, Italy.
Abstract
PURPOSE: Using a recently developed matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI-IMS) method, human breast cancer formalin-fixed paraffin-embedded (FFPE) tissue sections and tissue microarrays (TMA) are evaluated for N-linked glycan distribution in the tumor microenvironment. EXPERIMENTAL DESIGN: Tissue sections representing multiple human epidermal growth factor receptor 2 (HER2) receptor-positive and triple-negative breast cancers (TNBC) in both TMA and FFPE slide format are processed for high resolution N-glycan MALDI-IMS. An additional FFPE tissue cohort of primary and metastatic breast tumors from the same donors are also evaluated. RESULTS: The cumulative N-glycan MALDI-IMS analysis of breast cancer FFPE tissues and TMAs indicate the distribution of specific glycan structural classes to stromal, necrotic, and tumor regions. A series of high-mannose, branched and fucosylated glycans are detected predominantly within tumor regions. Additionally, a series of polylactosamine glycans are detected in advanced HER2+, TNBC, and metastatic breast cancer tissues. Comparison of tumor N-glycan species detected in paired primary and metastatic tissues indicate minimal changes between the two conditions. CONCLUSIONS AND CLINICAL RELEVANCE: The prevalence of tumor-associated polylactosamine glycans in primary and metastatic breast cancer tissues indicates new mechanistic insights into the development and progression of breast cancers. The presence of these glycans could be targeted for therapeutic strategies and further evaluation as potential prognostic biomarkers.
PURPOSE: Using a recently developed matrix-assisted laser desorption/ionization imaging mass spectrometry (MALDI-IMS) method, human breast cancer formalin-fixed paraffin-embedded (FFPE) tissue sections and tissue microarrays (TMA) are evaluated for N-linked glycan distribution in the tumor microenvironment. EXPERIMENTAL DESIGN: Tissue sections representing multiple human epidermal growth factor receptor 2 (HER2) receptor-positive and triple-negative breast cancers (TNBC) in both TMA and FFPE slide format are processed for high resolution N-glycan MALDI-IMS. An additional FFPE tissue cohort of primary and metastatic breast tumors from the same donors are also evaluated. RESULTS: The cumulative N-glycan MALDI-IMS analysis of breast cancer FFPE tissues and TMAs indicate the distribution of specific glycan structural classes to stromal, necrotic, and tumor regions. A series of high-mannose, branched and fucosylated glycans are detected predominantly within tumor regions. Additionally, a series of polylactosamine glycans are detected in advanced HER2+, TNBC, and metastatic breast cancer tissues. Comparison of tumor N-glycan species detected in paired primary and metastatic tissues indicate minimal changes between the two conditions. CONCLUSIONS AND CLINICAL RELEVANCE: The prevalence of tumor-associated polylactosamine glycans in primary and metastatic breast cancer tissues indicates new mechanistic insights into the development and progression of breast cancers. The presence of these glycans could be targeted for therapeutic strategies and further evaluation as potential prognostic biomarkers.
Authors: David G Hicks; Sarah M Short; Nichole L Prescott; Shannon M Tarr; Kara A Coleman; Brian J Yoder; Joseph P Crowe; Toni K Choueiri; Andrea E Dawson; G Thomas Budd; Raymond R Tubbs; Graham Casey; Robert J Weil Journal: Am J Surg Pathol Date: 2006-09 Impact factor: 6.394
Authors: Danielle A Scott; Kim Norris-Caneda; Laura Spruill; Evelyn Bruner; Yuko Kono; Peggi M Angel; Anand S Mehta; Richard R Drake Journal: Int J Mass Spectrom Date: 2018-01-09 Impact factor: 1.986
Authors: A T R Clark; V M L Guimarães da Costa; L Bandeira Costa; C L Bezerra Cavalcanti; M J B De Melo Rêgo; E I C Beltrão Journal: Eur J Histochem Date: 2014-05-26 Impact factor: 3.188
Authors: Alyson P Black; Hongyan Liang; Connor A West; Mengjun Wang; Harmin P Herrera; Brian B Haab; Peggi M Angel; Richard R Drake; Anand S Mehta Journal: Anal Chem Date: 2019-06-20 Impact factor: 6.986
Authors: Denys Rujchanarong; Danielle Scott; Yeonhee Park; Sean Brown; Anand S Mehta; Richard Drake; George E Sandusky; Harikrishna Nakshatri; Peggi M Angel Journal: Front Oncol Date: 2022-06-27 Impact factor: 5.738
Authors: Peggi M Angel; Janet Saunders; Cassandra L Clift; Shai White-Gilbertson; Christina Voelkel-Johnson; Elizabeth Yeh; Anand Mehta; Richard R Drake Journal: J Proteome Res Date: 2019-09-19 Impact factor: 4.466
Authors: Calvin R K Blaschke; Colin T McDowell; Alyson P Black; Anand S Mehta; Peggi M Angel; Richard R Drake Journal: Clin Lab Med Date: 2021-04-24 Impact factor: 2.172
Authors: Calvin R K Blaschke; Alyson P Black; Anand S Mehta; Peggi M Angel; Richard R Drake Journal: J Am Soc Mass Spectrom Date: 2020-08-18 Impact factor: 3.109